Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Oct 10:2:60.
doi: 10.3389/fphar.2011.00060. eCollection 2011.

Current medical treatments for juvenile idiopathic arthritis

Nicolino Ruperto  1 , Alberto Martini
Affiliations

Current medical treatments for juvenile idiopathic arthritis

Nicolino Ruperto et al. Front Pharmacol. .

Abstract

Juvenile idiopathic arthritis (JIA) differs markedly from adult rheumatoid arthritis. It is not a single disease, but an exclusion diagnosis that gather together all forms of arthritis that begin before the age of 16 years, persist for more than 6 weeks, and are of unknown origin. The advent of the new biological treatments has dramatically changed both the observed responses to treatment and the expectations of therapies. The implementation of an adequate legislation as well as the presence of international research networks of pediatric rheumatology have contributed to foster the conduct of controlled clinical trials and the development of validated outcome measures. This review will currently describe the methodological approach for performing clinical trials in JIA as well as the current available drug treatment.

Keywords: biological agents; joint damage; juvenile idiopathic arthritis; small molecules.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Barnes M. G., Grom A. A., Thompson S. D., Griffin T. A., Luyrink L. K., Colbert R. A., Glass D. N. (2010). Biologic similarities based on age at onset in oligoarticular and polyarticular subtypes of juvenile idiopathic arthritis. Arthritis Rheum. 62, 3249–325810.1002/art.27657 - DOI - PMC - PubMed
    1. Bartoli M., Taro M., Magni-Manzoni S., Pistorio A., Traverso F., Viola S., Magnani A., Gasparini C., Martini A., Ravelli A. (2008). The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis. Ann. Rheum. Dis. 67, 370–37410.1136/ard.2007.073445 - DOI - PubMed
    1. Bernatsky S., Rosenberg A. M., Oen K. G., Duffy C. M., Ramsey-Goldman R., Labrecque J., St Pierre Y., Clarke A. E. (2011). Malignancies in juvenile idiopathic arthritis: a preliminary report. J. Rheumatol. 38, 760–763 - PubMed
    1. Beukelman T., Patkar N. M., Saag K. G., Tolleson-Rinehart S., Cron R.Q., DeWitt E. M., Ilowite N. T., Kimura Y., Laxer R. M., Lovell D. J., Martini A., Rabinovich C. E., Ruperto N. (2011a). American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. (Hoboken) 63, 465–48210.1002/acr.20460 - DOI - PMC - PubMed
    1. Beukelman T., Cron R. Q., Patkar N. M., Saag K. G., Dewitt E. M., Lovell D. J., Ilowite N. T., Kimura Y., Laxer R. M., Martini A., Ruperto N., Rabinovich C. E. (2011b). ACR recommendations for the treatment of JIA: author reply to the comment by professor Huppertz. Arthritis Care Res. (Hoboken) 63, 1355–135610.1002/acr.20460 - DOI - PMC - PubMed

LinkOut - more resources